[Federal Register Volume 70, Number 150 (Friday, August 5, 2005)]
[Notices]
[Page 45407]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 05-15540]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Development and Use of 
Cripto-1 as a Biomarker and Treatment for Neurodegenerative Disease

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health, Department 
of Health and Human Services, is contemplating the grant of an 
exclusive patent license to practice the inventions embodied in U.S. 
Patent Application 60/508,750, filed October 3, 2003 [DHHS Ref. E-075-
2003/0-US-01] and PCT Application PCT/US04/32649 [DHHS Ref. E-075-2003/
0-PCT-02], entitled Use of Cripto-1 as a Biomarker for 
Neurodegenerative Disease and Method of Inhibiting Progression Thereof, 
to Neuronascent, Inc., which is located in Clarksville, Maryland. The 
patent rights in these inventions have been assigned to the United 
States of America.
    The prospective exclusive license territory may be worldwide and 
the field of use may be limited to the development and use of Cripto 
small molecule inhibitors to treat and prevent Alzheimer's disease in 
humans.

DATES: Only written comments and/or applications for a license, which 
are received by the NIH Office of Technology Transfer on or before 
October 4, 2005 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
comments, and other materials relating to the contemplated exclusive 
license should be directed to: Michelle A. Booden, Ph.D., Technology 
Licensing Specialist, Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
MD 20852-3804; telephone: (301) 451-7337; Facsimile: (301) 402-0220; e-
mail: [email protected].

SUPPLEMENTARY INFORMATION: The technology relates to another use of 
Cripto-1 as a biomarker and possible therapeutic target for a variety 
of neurodegenerative diseases, including NeuroAids, Alzheimer's 
disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Parkinson's 
disease and encephalitis. Cripto-1 appears to be overexpressed by 20-
fold or more in NeuroAids and as such, may be enhanced in other 
inflammatory neurological diseases, and thus assist in the early 
detection of neurological changes associated with these diseases, as 
well as a possible therapeutic target for slowing progression.
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless within sixty 
(60) days from the date of this published notice, the NIH receives 
written evidence and argument that establishes that the grant of the 
license would not be consistent with the requirements of 35 U.S.C. 209 
and 37 CFR 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: July 28, 2005.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 05-15540 Filed 8-4-05; 8:45 am]
BILLING CODE 4140-01-P